Perceptive Advisors Llc - Jun 29, 2022 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Signature
/s/ Joseph Edelman - for Perceptive Life Sciences Master Fund Ltd., By: Perceptive Advisors LLC, its investment manager, By: Joseph Edelman, its managing member
Stock symbol
ATHA
Transactions as of
Jun 29, 2022
Transactions value $
$4,100,372
Form type
4
Date filed
7/1/2022, 02:24 PM
Previous filing
Jun 27, 2022
Next filing
Jul 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATHA Common Stock Purchase $807K +270K +7.88% $2.99 3.7M Jun 29, 2022 See Footnote F1, F3
transaction ATHA Common Stock Purchase $3.29M +1.1M +29.8% $2.99 4.8M Jun 30, 2022 See Footnote F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.83 to $3.00, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range.
F2 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.87 to $3.00, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range.
F3 The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.